Recursion (NASDAQ: RXRX) began Wednesday down in its stock price. The company purporting to be a leading clinical stage TechBio company decoding biology to radically improve lives, today announced the generation of screening libraries leveraging tools within its AI/ML platform, the Recursion OS, with Enamine’s REAL Space, the world’s largest source of make-on-demand small molecules.
Together, the two companies have curated 10 enriched screening libraries from over 15,000 newly synthesized compounds designed to accelerate drug discovery against 100 key and clinically relevant drug targets in difficult to address biological areas.
Enamine’s REAL Space represents the continuously expanding chemical library built on insights from millions of parallel syntheses. While the chemical space offers incredible potential, the sheer volume of compounds, numbering in the tens of billions, makes it difficult to select the most promising candidates. By combining the expansive REAL Space with the Recursion OS to predict small molecule compatibility with protein targets, the collaboration allows for the creation of smaller, highly focused libraries that outperform traditional high-throughput screening (HTS) collections.
“We have been using the Recursion OS to identify compounds across Enamine’s vast chemical space for our own internal discovery needs,” said CEO Chris Gibson. “This collaboration allows us to extend that approach to areas of biology that are of general interest to the industry.”
RXRX shares fell 8.5 cents, or 2.1%, to $3.85.